REFERENCES
1. van Dessel LF, van Riet J, Smits M, et al. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. Nat Commun 2019;10:5251.
2. Lavallee L, Morash C, Saad F, et al. Real-world management of metastatic castration-resistant prostate cancer (mCRPC): a national multicenter cohort study. JCO 2022;40:252-252.
3. Huang X, Chau CH, Figg WD. Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol 2012;5:35.
4. Nuhn P, De Bono JS, Fizazi K, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol 2019;75:88-99.
5. Peyraud F, Italiano A. Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel) 2020;12:1502.
6. Yehya A, Ghamlouche F, Zahwe A, et al. Drug resistance in metastatic castration-resistant prostate cancer: an update on the status quo. Cancer Drug Resist 2022;5:667-90.
7. Kumar A, Kumar P, Sharma M, et al. Role of extracellular vesicles secretion in paclitaxel resistance of prostate cancer cells. Cancer Drug Resist 2022;5:612-24.
8. Kushwaha PP, Verma S, Kumar S, Gupta S. Role of prostate cancer stem-like cells in the development of antiandrogen resistance. Cancer Drug Resist 2022;5:459-71.
9. Choi WW, Boland JL, Lin J. ONECUT2 as a key mediator of androgen receptor-independent cell growth and neuroendocrine differentiation in castration-resistant prostate cancer. Cancer Drug Resist 2022;5:165-70.
10. Khalil MI, De Benedetti A. Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance. Cancer Drug Resist 2022;5:93-101.
